GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clal Biotechnology Industries Ltd (XTAE:CBI) » Definitions » 5-Year ROIIC %

Clal Biotechnology Industries (XTAE:CBI) 5-Year ROIIC % : -6.70% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Clal Biotechnology Industries 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Clal Biotechnology Industries's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was -6.70%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Clal Biotechnology Industries's 5-Year ROIIC % or its related term are showing as below:

XTAE:CBI's 5-Year ROIIC % is ranked better than
55.57% of 1373 companies
in the Biotechnology industry
Industry Median: -19.48 vs XTAE:CBI: -6.70

Clal Biotechnology Industries 5-Year ROIIC % Historical Data

The historical data trend for Clal Biotechnology Industries's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clal Biotechnology Industries 5-Year ROIIC % Chart

Clal Biotechnology Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -70.42 -15.59 -19.29 -3.16 -6.70

Clal Biotechnology Industries Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -3.16 - -6.70

Competitive Comparison of Clal Biotechnology Industries's 5-Year ROIIC %

For the Biotechnology subindustry, Clal Biotechnology Industries's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clal Biotechnology Industries's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clal Biotechnology Industries's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Clal Biotechnology Industries's 5-Year ROIIC % falls into.



Clal Biotechnology Industries 5-Year ROIIC % Calculation

Clal Biotechnology Industries's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -10.181 (Dec. 2023) - -60.332146 (Dec. 2018) )/( 149.755 (Dec. 2023) - 898.703 (Dec. 2018) )
=50.151146/-748.948
=-6.70%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Clal Biotechnology Industries  (XTAE:CBI) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Clal Biotechnology Industries 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Clal Biotechnology Industries's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clal Biotechnology Industries (XTAE:CBI) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.

Clal Biotechnology Industries (XTAE:CBI) Headlines

From GuruFocus

This Warren Buffett Bargain Stock Is Good For A Double

By Jonathan Poland Jonathan Poland 05-27-2015

Van Den Berg Almost Sells Out 4 Stakes in 1st Quarter

By David Goodloe David Goodloe 04-20-2016

Does the Increase in Volatility Signal a Dangerous Market Environment?

By Chuck Carnevale Chuck Carnevale 11-11-2016

Dollar Cost Average on CBI

By Jonathan Poland Jonathan Poland 08-17-2017

McDermott Awarded Paraxylene (pX) Technology Contract in China

By PRNewswire PRNewswire 06-13-2019

Should We Devote Attention to Market Factors?

By Grahamites Grahamites 08-25-2015